Screened 2026-08-20 · the tape above runs as of 16:37 UTC · 29 Aug · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Pfizer holds its Accumulation at $27.79. Consolidating, no directional conviction, held for 3 days.
As held on the ledger · 2026-08-20
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price at the screen
$27.79
Valuation
36.57 trailing · 9.60 forward price to earnings
Values screen
PASS· score 84.1
Beta
0.28
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.73%
Below 33%
Interest-bearing debt is just 30.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.64%
Below 33%
Cash held in interest-bearing accounts and securities is 0.6% of assets, under the one-third limit.
Pass
Receivables
6.25%
Below 49%
Money owed to the company is 6.3% of assets, under the 49% limit.
Pass
Revenue purity
0.96%
Below 5%
Only 1.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 26% discount to our $35.00 fair value, narrow competitive moat, 2.60% revenue growth.
Fair value range in USD, drawn from the 2026-08-20 screen. The gold marker is the market price at the same screen. A 25.9% margin of safety to the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +1% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-20 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pfizer, the Healer with a Valued Touch
Picture a drugstore shelf, and Pfizer products are likely there. From fighting diseases to improving lives, Pfizer's impact is tangible. With a forward P/E of 9.6x, the market is undervaluing a company with a 3% revenue growth and a 7% profit margin. Our fair value sits at $35.00, indicating a 26% margin of safety. Why it stands out is not just its global reach but also its ethical standing - it passes our ethical screen, aligning profits with principles.
Yet, this is no fairy tale. Pfizer's return on equity (ROE) at 5% and a narrow moat suggest it's not a market fortress; it's more of a swift river, navigating competitive landscapes. The risk here is the company's reliance on a few key products and the ever-present threat of patent expirations, which could erode margins. The consensus rating from 26 analysts is a 'buy', with a median target of $28, slightly below our fair value estimate.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PFE trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-07-28Distribution$24.54+0.0%Entry 10
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Distribution$24.54+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Distribution$24.54+0.0%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Distribution$24.54-2.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Distribution$25.05+0.0%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Distribution$25.05+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markdown$26.04+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (27 analysts) rates it buy, with a mean price target of $29.
2026-07-03Markdown$26.04+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$26.04Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
